Dr Sara Tolaney

Go Back

Medical Oncology

  • Dana-Farber Cancer Institute/Harvard Medical School
  • location United States

Sara Tolaney, MD, MPH is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and is internationally recognized for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Dr Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Masters in Public Health from Harvard School of Public Health.

Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She currently chairs several registration studies in these areas and also leads many investigator-initiated trials. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals such as the New England Journal, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology.

Dr Sara Tolaney has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consulting or Advisory Role: Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi Sankyo, Gilead, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Myovant, Zetagen, Umoja Biopharma, Menarini/Stemline, Aadi Biopharma, Bayer

Research Funding: Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Gilead, Seattle Genetics, OncoPep

Programmes developed by Dr Sara Tolaney

eks
Experts Knowledge Share Video

Episode

2

of 4

episode
Oncology 
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer

Episode 2: Optimisation of Treatment Selection & Sequencing Decisions in ER+/HER2- Advanced or Metastatic Breast Cancer

Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca
Endorsed by
SOLTI
GRASP
  • clock 14 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology
video Video

Episode

3

of 4

episode
Oncology 
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer

Episode 3: ESR1 Mutation: The Need for & Role of Testing in ER+/HER2- Advanced or Metastatic Breast Cancer

Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca
Endorsed by
SOLTI
GRASP
  • clock 20 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology
video Video

Episode

4

of 4

episode
Oncology 
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer

Episode 4: Panel Discussion and Summary

Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca
Endorsed by
SOLTI
GRASP
  • clock 19 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology
video Video

Episode

1

of 4

episode
Oncology 
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer

Episode 1: Overview of Clinical Data of SERDs & Their Place in Treatment Landscape

Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca
Endorsed by
SOLTI
GRASP
  • download Downloadable
    Resources
  • clock 18 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology